Wendel Bruce 4
4 · Abraxis BioScience, Inc. · Filed Oct 19, 2010
Insider Transaction Report
Form 4
Wendel Bruce
Exec. VP Corporate Development
Transactions
- Award
Common Stock
2010-10-15+50,000→ 119,784 total - Disposition to Issuer
Common Stock
2010-10-15−119,784→ 0 total - Disposition to Issuer
Stock Option (Right to buy)
2010-10-15$33.21/sh−138,125$4,587,131→ 0 totalExercise: $39.93From: 2010-10-01Exp: 2015-03-15→ Common Stock (138,125 underlying) - Disposition to Issuer
Stock Option (Right to buy)
2010-10-15$7.41/sh−10,607$78,598→ 0 totalExercise: $65.73From: 2007-11-29Exp: 2014-08-09→ Common Stock (10,607 underlying) - Disposition to Issuer
Stock Option (Right to buy)
2010-10-15$1.12/sh−4,242$4,751→ 0 totalExercise: $72.02From: 2007-11-29Exp: 2016-04-17→ Common Stock (4,242 underlying) - Disposition to Issuer
Stock Option (Right to buy)
2010-10-15$2.51/sh−2,121$5,324→ 0 totalExercise: $70.63From: 2007-11-29Exp: 2016-05-19→ Common Stock (2,121 underlying) - Disposition to Issuer
Stock Option (Right to buy)
2010-10-15$8.15/sh−3,678$29,976→ 0 totalExercise: $64.99From: 2008-11-05Exp: 2018-11-05→ Common Stock (3,678 underlying)
Footnotes (4)
- [F1]Represents shares of Restricted Stock Units that vested in connection with the closing of the Agreement and Plan of Merger, dated as of June 30, 2010, among Celgene Corporation ("Celgene"), Artistry Acquisition Corp. ("Merger Sub") and Abraxis BioScience, Inc. ("Abraxis"), whereby Merger Sub merged into Abraxis, with Abraxis continuing as the surviving company and a wholly owned subsidiary of Celgene (the "Merger"). Each Restricted Stock Unit represents a right to receive one share of ABII common stock.
- [F2]Includes shares subject Restricted Stock Units.
- [F3]Includes shares and Restricted Stock Units. Shares disposed of pursuant to the Merger in exchange for (i) an amount in cash equal to $58.00, (ii) 0.2617 of a share of Celgene common stock and (iii) a contingent value right issued by Celgene. Restricted Stock Units disposed of pursuant to the Merger in exchange for (i) an amount in cash equal to $73.14 and (ii) a contingent value right issued by Celgene.
- [F4]Pursuant to the Merger, this option, which was cancelled at the effective time of the Merger in exchange for (i) a cash payment equal to the excess of $73.14 per share over the exercise price per share of this option and (ii) a contingent value right issued by Celgene.